Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

490 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
MHC class II-restricted antigen presentation is required to prevent dysfunction of cytotoxic T cells by blood-borne myeloids in brain tumors.
Kilian M, Sheinin R, Tan CL, Friedrich M, Krämer C, Kaminitz A, Sanghvi K, Lindner K, Chih YC, Cichon F, Richter B, Jung S, Jähne K, Ratliff M, Prins RM, Etminan N, von Deimling A, Wick W, Madi A, Bunse L, Platten M. Kilian M, et al. Among authors: lindner k. Cancer Cell. 2023 Feb 13;41(2):235-251.e9. doi: 10.1016/j.ccell.2022.12.007. Epub 2023 Jan 12. Cancer Cell. 2023. PMID: 36638785 Free article.
Intrathecal activation of CD8+ memory T cells in IgG4-related disease of the brain parenchyma.
Friedrich M, Kehl N, Engelke N, Kraus J, Lindner K, Münch P, Mildenberger I, Groden C, Gass A, Etminan N, Fatar M, von Deimling A, Reuss D, Platten M, Bunse L. Friedrich M, et al. Among authors: lindner k. EMBO Mol Med. 2021 Aug 9;13(8):e13953. doi: 10.15252/emmm.202113953. Epub 2021 Jul 13. EMBO Mol Med. 2021. PMID: 34254741 Free PMC article.
AMPLIFY-NEOVAC: a randomized, 3-arm multicenter phase I trial to assess safety, tolerability and immunogenicity of IDH1-vac combined with an immune checkpoint inhibitor targeting programmed death-ligand 1 in isocitrate dehydrogenase 1 mutant gliomas.
Bunse L, Rupp AK, Poschke I, Bunse T, Lindner K, Wick A, Blobner J, Misch M, Tabatabai G, Glas M, Schnell O, Gempt J, Denk M, Reifenberger G, Bendszus M, Wuchter P, Steinbach JP, Wick W, Platten M. Bunse L, et al. Among authors: lindner k. Neurol Res Pract. 2022 May 23;4(1):20. doi: 10.1186/s42466-022-00184-x. Neurol Res Pract. 2022. PMID: 35599302 Free PMC article.
T cell receptor dynamic and transcriptional determinants of T cell expansion in glioma-infiltrating T cells.
Lu KH, Michel J, Kilian M, Aslan K, Qi H, Kehl N, Jung S, Sanghvi K, Lindner K, Zhang XW, Green EW, Poschke I, Ratliff M, Bunse T, Sahm F, von Deimling A, Wick W, Platten M, Bunse L. Lu KH, et al. Among authors: lindner k. Neurooncol Adv. 2022 Aug 31;4(1):vdac140. doi: 10.1093/noajnl/vdac140. eCollection 2022 Jan-Dec. Neurooncol Adv. 2022. PMID: 36196364 Free PMC article.
A H3K27M-targeted vaccine in adults with diffuse midline glioma.
Grassl N, Poschke I, Lindner K, Bunse L, Mildenberger I, Boschert T, Jähne K, Green EW, Hülsmeyer I, Jünger S, Kessler T, Suwala AK, Eisele P, Breckwoldt MO, Vajkoczy P, Grauer OM, Herrlinger U, Tonn JC, Denk M, Sahm F, Bendszus M, von Deimling A, Winkler F, Wick W, Platten M, Sahm K. Grassl N, et al. Among authors: lindner k. Nat Med. 2023 Oct;29(10):2586-2592. doi: 10.1038/s41591-023-02555-6. Epub 2023 Sep 21. Nat Med. 2023. PMID: 37735561 Free PMC article.
MediMer: a versatile do-it-yourself peptide-receptive MHC class I multimer platform for tumor neoantigen-specific T cell detection.
Meyer M, Parpoulas C, Barthélémy T, Becker JP, Charoentong P, Lyu Y, Börsig S, Bulbuc N, Tessmer C, Weinacht L, Ibberson D, Schmidt P, Pipkorn R, Eichmüller SB, Steinberger P, Lindner K, Poschke I, Platten M, Fröhling S, Riemer AB, Hassel JC, Roberti MP, Jäger D, Zörnig I, Momburg F. Meyer M, et al. Among authors: lindner k. Front Immunol. 2024 Jan 4;14:1294565. doi: 10.3389/fimmu.2023.1294565. eCollection 2023. Front Immunol. 2024. PMID: 38239352 Free PMC article.
H3K27M neoepitope vaccination in diffuse midline glioma induces B and T cell responses across diverse HLA loci of a recovered patient.
Boschert T, Kromer K, Lerner T, Lindner K, Haltenhof G, Tan CL, Jähne K, Poschke I, Bunse L, Eisele P, Grassl N, Mildenberger I, Sahm K, Platten M, Lindner JM, Green EW. Boschert T, et al. Among authors: lindner k. Sci Adv. 2024 Feb 2;10(5):eadi9091. doi: 10.1126/sciadv.adi9091. Epub 2024 Feb 2. Sci Adv. 2024. PMID: 38306431 Free PMC article.
Prediction of tumor-reactive T cell receptors from scRNA-seq data for personalized T cell therapy.
Tan CL, Lindner K, Boschert T, Meng Z, Rodriguez Ehrenfried A, De Roia A, Haltenhof G, Faenza A, Imperatore F, Bunse L, Lindner JM, Harbottle RP, Ratliff M, Offringa R, Poschke I, Platten M, Green EW. Tan CL, et al. Among authors: lindner k. Nat Biotechnol. 2024 Mar 7. doi: 10.1038/s41587-024-02161-y. Online ahead of print. Nat Biotechnol. 2024. PMID: 38454173
The Outcome of Ex Vivo TIL Expansion Is Highly Influenced by Spatial Heterogeneity of the Tumor T-Cell Repertoire and Differences in Intrinsic In Vitro Growth Capacity between T-Cell Clones.
Poschke IC, Hassel JC, Rodriguez-Ehrenfried A, Lindner KAM, Heras-Murillo I, Appel LM, Lehmann J, Lövgren T, Wickström SL, Lauenstein C, Roth J, König AK, Haanen JBAG, van den Berg J, Kiessling R, Bergmann F, Flossdorf M, Strobel O, Offringa R. Poschke IC, et al. Clin Cancer Res. 2020 Aug 15;26(16):4289-4301. doi: 10.1158/1078-0432.CCR-19-3845. Epub 2020 Apr 17. Clin Cancer Res. 2020. PMID: 32303540
Characterization of adrenal chromaffin progenitor cells in mice.
Deimling F, Finotto S, Lindner K, Brühl B, Roig-Lopez JL, Garcia-Arraras JE, Goridis C, Krieglstein K, Unsicker K. Deimling F, et al. Among authors: lindner k. Adv Pharmacol. 1998;42:932-5. doi: 10.1016/s1054-3589(08)60900-x. Adv Pharmacol. 1998. PMID: 9328051 No abstract available.
490 results